HLA-DRB1 and myeloid sarcoma: However, specific antigens in MS have yet to be defined35, which hinders the elucidation of the mechanisms underlying susceptibility conferred by the major risk haplotype DRB1*15:01, as well as development of antigen-specific therapies.